Ophthalmology Times - Ophthalmology news, articles, and events
WEBBy Alice Epitropoulos, MD. September 15th 2024. Common glaucoma treatments may worsen ocular surface disease and meibomian gland dysfunction, leading to discomfort, redness, and even poor treatment compliance. Ophthalmology Times - ophthalmology news, articles, and events in a timely and accurate manner for members of the …
Physicians sort out pros and cons of several new IOLs on the market
WEBNov 12, 2021 · The new IOL in the EDoF category is the AcrySof IQ Vivity (Alcon). The Vivity uses wavefront-shaping technology on its anterior surface that elongates the depth of focus, giving about a 1.5 D range of vision. Because it is a nondiffractive lens, risks of glare and halos are minimized and quality of vision is better than with a multifocal IOL.
Myths and misconceptions about autologous serum for dry eye
WEBJun 22, 2020 · Special to Ophthalmology Times® Autologous serum eye drops (ASEDs) have become a mainstay of therapy for certain categories of patients with dry eye and those with underlying immunologic disease or poor epithelial healing.. The logistics of prescribing ASEDs have changed dramatically in the past few years, making their use far more …
News - Ophthalmology Times
WEBRipple Therapeutics and AbbVie collaborate in development of RTC-620 for IOP reduction in patients with open-angle glaucoma. September 19th 2024. Ripple will lead preclinical development of RTC-620 while AbbVie will lead the clinical and commercialization activities upon exercise of option-to-license agreement.
FDA approves eye drops for treatment of presbyopia
WEBOct 30, 2021 · Allergan developed VUITY, which it noted is the first and only FDA-approved eye drop to treat presbyopia. Allergan, an AbbVie company, announced FDA approval of pilocarpine HCl ophthalmic solution 1.25% (VUITY) for the treatment of presbyopia, commonly known as age-related blurry near vision, in adults. According to the company, …
Identifying, managing dysphotopsia after cataract surgery
WEBApr 25, 2014 · Boston — Following cataract surgery, patients can present with a variety of visual complaints-i.e., dysphotopsias, aberrant optical phenomena that interfere with vision after IOL implantation. Positive dysphotopsias include rainbows, streaks, crescents, rings, halos, and veiling glare, haze, and fog. Negative dysphotopsias are relative and ...
Breaking down the dorzolamide shortage - Ophthalmology Times
WEBAug 9, 2019 · Essentially, brimonidine 0.1% (Alphagan P, Allergan) is often a reasonable substitution for dorzolamide, while brimonidine-timolol (Combigan, Allergan) is an ideal substitution for dorzolamide-timolol shortages, assuming no brimonidine allergy. Certainly, the dorzolamide shortage has helped us view branded pharmaceutical companies in a …
Combination eye drop manages inflammation and infection after …
WEBApr 23, 2022 · Blake K. Williamson, MD, MPH, MS, and coauthor Urvi Patel, BSc, presented an e-poster at the American Society of Cataract and Refractive Surgery’s 2022 annual meeting in Washington, D.C., on the efficacy of a combination eye drop comprised of an antibiotic, anti-inflammatory and lubricant as part of a postoperative treatment …
Dry eye paradise: FDA green-lights Miebo as first and only eye …
WEBJun 21, 2023 · According to the companies, perfluorohexyloctane ophthalmic solution is the first and only FDA-approved treatment for DED that directly targets tear evaporation instead of tear formation. Formerly known as NOV03, the drug was developed by Novaliq, and Bausch + Lomb attained exclusive licensing in the United States and Canada in 2019. 12.
Treating vitreous opacities with YAG laser vitreolysis
WEBJan 18, 2021 · This article was reviewed by Netan Choudhry, MD, FRCSC YAG laser vitreolysis is a less-invasive option than pars plana vitrectomy for patients who are affected by vitreous opacities (floaters), according to Netan Choudhry, MD, FRCSC, of Vitreous Retina Macula Specialists of Toronto. Although floaters are typically clinically …